Skip to main content

Does Austedo cause Parkinson's Disease?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on Aug 9, 2025.

Official Answer by Drugs.com

Austedo does not cause Parkinson’s disease. However, it may cause Parkinson-like symptoms—including tremor, muscle stiffness, slow movement, and difficulties with balance—in some patients. These effects are known as drug-induced parkinsonism and are usually reversible after stopping or reducing the medication.

Why These Symptoms Occur

Austedo (deutetrabenazine) works by inhibiting vesicular monoamine transporter 2 (VMAT2). VMAT2 controls dopamine movement within the brain. By blocking VMAT2, Austedo decreases the amount of dopamine available to brain cells. Dopamine is essential for smooth, coordinated movement, and its reduction can lead to symptoms resembling those of Parkinson’s disease—such as tremor, muscle rigidity, and slowed movements (bradykinesia). This side effect is called drug-induced parkinsonism, and is distinct from Parkinson’s disease itself.

Key Difference from Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disorder where dopamine-producing brain cells gradually deteriorate. Symptoms worsen over time and persist even without medication.

Drug-induced parkinsonism is a reaction to medications that alter dopamine levels. It typically appears shortly after starting or increasing the dose of Austedo, and most cases improve or resolve completely when the drug is stopped or its dose is lowered.

What Symptoms to Watch For

If you take Austedo, monitor for these symptoms:

Patients should contact their healthcare provider promptly if they notice new or worsening movement problems. Dose adjustments or discontinuation may be necessary, and your doctor can help distinguish between medication side effects and the underlying disease.

Related questions

Who Is at Greater Risk?

Not everyone taking Austedo will experience Parkinson-like symptoms, but certain individuals are more susceptible than others. Understanding these risk factors can help patients and healthcare providers monitor more closely and take steps to reduce the likelihood or severity of side effects. Those at an increased risk include:

FDA and Clinical Evidence

The FDA label for Austedo clearly states that the drug can cause parkinsonism, particularly in people being treated for Huntington’s disease or tardive dyskinesia. Post-marketing data and clinical trials confirm that these symptoms generally appear within the first two weeks of starting or increasing the dose of Austedo. Importantly, they typically resolve when the drug is stopped or dose is reduced. Healthcare providers are advised to monitor for these effects and manage them appropriately as part of safe clinical use.

Conclusion

Austedo does not cause Parkinson’s disease. What it can cause—most often reversibly—is drug-induced parkinsonism, with symptoms that mimic Parkinson’s but are a temporary side effect. Always consult your healthcare provider if you experience movement difficulties while using Austedo.

This is not all the information you need to know about Austedo for safe and effective use and does not take the place of your doctor’s directions. Review the full patient medication guide and discuss this information and any questions you have with your doctor or other health care provider.

References
  1. Austedo [package insert]. Updated February 2025. Teva Neuroscience, Inc. Accessed August 8, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0
  2. Lohr, K. M., & Miller, G. W. (2014). VMAT2 and Parkinson's disease: harnessing the dopamine vesicle. Expert review of neurotherapeutics, 14(10), 1115–1117. https://doi.org/10.1586/14737175.2014.960399

Read next

How long does it take for Austedo to work?

Austedo (deutetrabenazine) starts working within two weeks, according to results of phase III clinical trials, which were conducted in patients with chorea associated with Huntington’s disease and tardive dyskinesia. Continue reading

What condition is Austedo used to treat?

Austedo (deutetrabenazine) is an oral prescription medication approved to treat Huntington’s chorea and tardive dyskinesia (TD). Austedo is classified as a vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 a protein that controls transfer of chemical messengers (neurotransmitters) between nerves in the brain between. These neurotransmitters help to control normal body movement or motor function. Continue reading

How much does Ingrezza cost and will insurance cover it?

Ingrezza costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength, or an annual cost of $102,973 to $113,126 per year; however, most people do not pay this amount. People with commercial insurance may qualify for a $0 copay for each Ingrezza prescription through the INBRACE Support Program and approximately 46% of Medicare Part D and Medicare Advantage plans cover Ingrezza. For people with Medicaid, most states require prior authorization for Ingrezza and the satisfaction of certain criteria before it can be funded. Continue reading

See also:

Related medical questions

Drug information

Related support groups